Skip to main content

Driving a step change in the treatment of cancer for patients.


Step Pharma is focused on bringing STP938 to the patients who need it most. Step Pharma has recently begun clinical trials.

Clinical trials in lymphoma were started in 2H 2022.

Clinical trials will test the efficacy and safety of STP938 as a potential therapeutic to treat multiple cancers, both as a monotherapy or in combination with current and emerging therapies.

STP938 has entered clinical trials for the treatment of blood cancers where STP938 could form the backbone of various treatment regimens with the potential for accelerated approval from a single-arm Phase II study.

You can find information about our clinical trial – Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas here:


Learn more about us and our people.


Learn more about our lead CTPS1 Inhibitor.

Therapeutic Areas

Learn more about our therapeutic areas.


Get in touch with us.

Step Pharma
15 rue Louis et Auguste Lumière
Technoparc du Pays-de-Gex
01630 Saint-Genis-Pouilly